PMV Pharmaceuticals, Inc.

PMVP • Biotechnology

$1.29

— 0.00 (0.00%)

ResultadosÚltimo reporte: 30 jun 2026

PERFIL DE MAYOR RIESGOPrecauciónConfianza: 70%

Perfil cuantitativo — no constituye una recomendación de inversión.

Perfil cuantitativo — no constituye una recomendación de inversión.Metodología

Tesis del análisis: Conviene actuar con cautela. Los ratios recientes muestran debilidades que pueden limitar el retorno si los fundamentales no mejoran.

Capitalización

$68.87M

Crecimiento

—

Flujo de caja

0/5

Tendencia

Negative

Evidencia

Nivel de deuda manejable · 0.01Liquidez saludable · 10.09Rentabilidad débil

Datos financieros hasta: 30 jun 2026, 12:00 a.m. UTCÚltima actualización de earnings: 30 jun 2026, 12:00 a.m. UTCÚltima actualización del perfil: 16 ago 2026, 12:11 p.m. UTC

Resumen de la compañía

Valoración, calidad, fortaleza financiera, momentum y datos de analistas.

Price$1.29

Change0.00%

Shares Out53.39M

Market Cap$68.87M

Enterprise Value$-10.34M

52W Range1.02 - 1.88

Beta1.35

P/E-0.92

P/B0.96

P/FCF-0.97

EV/EBITDA0.13

EV/FCF0.15

Price$1.29

Change0.00%

Shares Out53.39M

Market Cap$68.87M

Enterprise Value$-10.34M

52W Range1.02 - 1.88

Beta1.35

P/E-0.92

P/B0.96

P/FCF-0.97

EV/EBITDA0.13

EV/FCF0.15

Earnings Yield-109.22%

FCF Yield-103.50%

Dividend Yield0.00%

Gross Margin0.00%

Oper. Margin0.00%

Profit Margin0.00%

Debt/Eq0.01

Current Ratio10.09

Quick Ratio10.09

Target$5.00

Target Upside287.60%

Target Median$5.00

Target Range5.00 - 5.00

Volume189.81K

Avg Volume357.06K

EPS Surprise0.07

ADN de inversión

Qué tan fuerte luce esta compañía para inversionistas de largo plazo

de 100

Calidad del negocio

Márgenes, ventaja competitiva, retornos

22/100

Fortaleza financiera

Deuda, caja, estabilidad

76/100

Potencial de crecimiento

Ingresos y expansión

50/100

Atractivo del precio

Barata o cara hoy

95/100

Por qué este puntaje▼

Nivel de deuda manejable · 0.01Liquidez saludable · 10.09Rentabilidad débil

Analyst view

Analyst sentiment and price target

PMVP

Analyst sentiment

Based on 4 analyst votes · 2026-09-05

100/100

Bullish

Hold

Bearish

Precio objetivo

2026-08-16

Bajo

$5.00

Promedio

$5.00

Mediana

$5.00

Alto

$5.00

Resumen de la compañía

IPO: 9/25/2020

Industria: Biotechnology

P/B i: 0.96

Deuda / Patrimonio i: 0.01

Margen operativo: 0.00%

Margen neto: 0.00%

ROE i: -

ROIC: -

Salud financiera

Puntaje15 / 20

Deuda / Patrimonio: 0.01

Ratio corriente: 10.09

Ratio rápido: 10.09

Estado: Good

Transacciones internas

Actividad reciente de ejecutivos e insiders

⚠ 3 venta interna de alto volumens detectadas

BAUM CHARLES M

Transacción: 06/04/2026

COMPRA

Cambio

+42,000

Precio

$1.19

Presentación

06/05/2026

Tipo

COMPRA

FLOWERS KIRSTEN

Transacción: 06/04/2026

COMPRA

Cambio

+42,000

Precio

$1.19

Presentación

06/05/2026

Tipo

COMPRA

Gallagher Carol Giltner

Transacción: 06/04/2026

VENTA

Cambio

-42,000

Precio

$1.19

Presentación

06/05/2026

Tipo

VENTA

Insider	Tipo	Cambio	Precio	Transacción	Presentación
BAUM CHARLES M	COMPRA	+42,000	$1.19	06/04/2026	06/05/2026
FLOWERS KIRSTEN	COMPRA	+42,000	$1.19	06/04/2026	06/05/2026
Gallagher Carol Giltner	VENTA	-42,000	$1.19	06/04/2026	06/05/2026
LEVINE ARNOLD J	COMPRA	+42,000	$1.19	06/04/2026	06/05/2026
Stelzer Laurie	COMPRA	+42,000	$1.19	06/04/2026	06/05/2026
Mack David Henry	COMPRA	+744,960	$1.53	03/05/2026	03/09/2026
Jalota Deepika	COMPRA	+303,310	$1.53	03/05/2026	03/09/2026
Ticktin Robert	COMPRA	+319,270	$1.53	03/05/2026	03/09/2026
Carulli Michael	COMPRA	+240,000	$1.53	03/05/2026	03/09/2026
Mack David Henry	VENTA	-220,643	$1.37	10/27/2025	10/29/2025
Mack David Henry	COMPRA	+220,643	$1.37	10/27/2025	10/29/2025
ORBIMED ADVISORS LLC	VENTA	-1,000,000	$1.52	10/23/2025	10/27/2025
ORBIMED ADVISORS LLC	VENTA	-500,000	$1.80	09/10/2025	09/12/2025
Mack David Henry	VENTA	-58,411	$1.06	07/01/2025	07/03/2025
Carulli Michael	VENTA	-28,249	$1.06	07/01/2025	07/03/2025
Jalota Deepika	VENTA	-33,065	$1.06	07/01/2025	07/03/2025
Ticktin Robert	VENTA	-23,151	$1.06	07/01/2025	07/03/2025
BAUM CHARLES M	COMPRA	+33,500	$0.95	06/05/2025	06/09/2025
FLOWERS KIRSTEN	COMPRA	+33,500	$0.95	06/05/2025	06/09/2025
Gallagher Carol Giltner	VENTA	-33,500	$0.95	06/05/2025	06/09/2025

Sobre la compañía

PMV Pharmaceuticals, Inc.

PMV Pharmaceuticals, Inc. operates as a precision oncology company focused on discovering and developing both small molecule and tumor-agnostic therapies to address p53 mutations in cancer patients. Their leading experimental drug, PC14586, is a small molecule designed to correct the p53 protein specifically when it contains the Y220C mutation, thereby restoring its natural, functional state. The company is also progressing a pipeline of other programs targeting various mutant p53 forms, including Wild-type p53 Induced-Phosphatase, R282W, R273H, and other prevalent p53 hotspot mutations. Originally known as PJ Pharmaceuticals, Inc., the firm rebranded to PMV Pharmaceuticals, Inc. in July 2013. The company was founded in 2013 and has its main operational base in Cranbury, New Jersey.

Fuente - Link

Competidores

ACRV ATYR BMEA CBUS IMUX LITS RLMD RPTX TCRX VXRT

Tamaño = capitalización · color = línea del gráfico

Rendimiento de peers · 1A

Top performers + empresa seleccionada

Ultimas Noticias

PMV Pharma Announces Pricing of Oversubscribed $50 Million Public Offering of Securities

PRINCETON, N.J., Aug. 31, 2026 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (“PMV Pharma” or the “Company”; Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule therapies targeting p53, announced today the pricing of an underwritten public offering consisting of (i) 22,055,000 shares of its common stock and, in lieu of common stock to certain investors, pre-funded warrants to purchase an aggregate of up to 19,900,000 shares of its common stock, and (ii) accompanying warrants to purchase an aggregate of 41,955,000 shares of common stock. The common stock and pre-funded warrants are being sold in combination with an accompanying warrant to purchase one share of common stock for each share of common stock or pre-funded warrant sold. The accompanying warrants have an initial exercise price of $1.21 per share, subject to adjustment following a specified regulatory milestone, are immediately exercisable from the date of issuance and will expire five years from the date of issuance.

GlobeNewsWire

PMV Pharma Announces Proposed Public Offering of Securities

PRINCETON, N.J., Aug. 31, 2026 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (“PMV Pharma” or the “Company”; Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule therapies targeting p53, announced today that it has commenced an underwritten public offering of shares of its common stock and accompanying warrants to purchase shares of its common stock and, in lieu of common stock, to certain investors, pre-funded warrants to purchase shares of its common stock and accompanying warrants to purchase shares of its common stock. All of the shares, pre-funded warrants and accompanying common stock warrants to be sold in the proposed offering are to be sold by PMV Pharma. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

GlobeNewsWire

PMV Pharmaceuticals Announces Updated Promising Rezatapopt Monotherapy Interim Ovarian Cancer Data From PYNNACLE Phase 2 Pivotal Trial

PRINCETON, N.J., Aug. 31, 2026 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (“PMV Pharma” or the “Company”; Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule therapies targeting p53, today announced updated interim ovarian cancer data from the Phase 2 pivotal portion of the PYNNACLE clinical trial. The multicenter, single-arm, registrational Phase 2 trial is assessing rezatapopt as monotherapy at a dose of 2000 mg once-daily in patients with TP53 Y220C advanced solid tumors.

GlobeNewsWire

PMV Pharmaceuticals (PMVP) Upgraded to Buy: What Does It Mean for the Stock?

PMV Pharmaceuticals (PMVP) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Zacks Investment Research

PMV Pharmaceuticals Reports Second Quarter 2026 Financial Results and Corporate Highlights

PRINCETON, N.J., Aug. 14, 2026 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (“PMV Pharma” or the “Company”; Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule therapies targeting p53, today reported financial results for the second quarter ended June 30, 2026, and provided a corporate update.

GlobeNewsWire

Sorpresas de ganancias

Período	Estimado	Real	Sorpresa
2026-05-12	-0.41	-0.34	0.07
2026-03-06	-0.4	-0.34	0.06
2025-11-12	-0.4	-0.4	0
2025-08-07	-0.39	-0.41	-0.02
2025-05-09	-0.37	-0.34	0.03
2025-03-03	-0.38	-0.45	-0.07
2024-11-07	-0.35	-0.37	-0.02
2024-08-08	-0.34	-0.02	0.32
2024-05-09	-0.35	-0.3	0.05
2024-02-29	-0.39	-0.31	0.08
2023-11-09	-0.45	-0.34	0.11
2023-08-09	-0.47	-0.38	0.09